Aurinia Pharmaceuticals (AUPH)
(Delayed Data from NSDQ)
$5.03 USD
-0.06 (-1.18%)
Updated Apr 24, 2024 04:00 PM ET
After-Market: $5.03 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
D Value A Growth C Momentum C VGM
Cash flow Statements
Fiscal Year End for Aurinia Pharmaceuticals Inc falls in the month of December.
All data in Millions except Per Share data.
Cash Flow From Operations, Investments & Financial Activities
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Cash Flow From Operations, Investments & Financial Activities |
|||||
Net Income (Loss) | -78.02 | -108.18 | -180.97 | -102.68 | -123.85 |
Depreciation/Amortization & Depletion | 11.65 | 2.71 | 2.76 | 1.37 | 1.43 |
Net Change from Assets/Liabilities | -5.61 | -6.82 | -21.63 | 4.52 | 2.13 |
Net Cash from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Operating Activities | 38.52 | 32.76 | 42.15 | 26.93 | 56.83 |
Net Cash From Operating Activities | -33.46 | -79.53 | -157.69 | -69.86 | -63.46 |
Property & Equipment | -0.72 | -0.29 | -0.30 | -5.67 | -0.10 |
Acquisition/ Disposition of Subsidiaries | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investments | 5.88 | -59.68 | -84.53 | -150.84 | 7.88 |
Other Investing Activities | -11.86 | -0.66 | -7.20 | -1.68 | -0.02 |
Net Cash from Investing Activities | -6.71 | -60.63 | -103.87 | -158.19 | 7.78 |
Uses of Funds
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Issuance (Repurchase) of Capital Stock | 4.90 | 2.43 | 221.11 | 194.38 | 236.87 |
Issuance (Repayment) of Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Increase (Decrease) Short-Term Debt | -10.03 | 0.00 | 0.00 | 0.00 | -0.13 |
Payment of Dividends & Other Distributions | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Financing Activities | 0.00 | 0.00 | 0.00 | 0.00 | 6.99 |
Net Cash from Financing Activities | -5.13 | 2.43 | 221.11 | 194.38 | 243.73 |
Effect of Exchange Rate Changes | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Change In Cash & Equivalents | -45.30 | -137.73 | -40.45 | -33.67 | 188.05 |
Cash at Beginning of Period | 94.17 | 231.90 | 272.35 | 306.02 | 117.97 |
Cash at End of Period | 48.88 | 94.17 | 231.90 | 272.35 | 306.02 |
Diluted Net EPS | -0.54 | -0.76 | -1.40 | -0.87 | -1.33 |
Fiscal Year End for Aurinia Pharmaceuticals Inc falls in the month of December.
All data in Millions except Per Share data.
Cash Flow From Operations, Investments & Financial Activities
3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 | |
---|---|---|---|---|---|
Cash Flow From Operations, Investments & Financial Activities |
|||||
Net Income (Loss) | NA | -78.02 | -51.15 | -37.70 | -26.21 |
Depreciation/Amortization & Depletion | NA | 11.65 | 6.70 | 1.24 | -1.89 |
Net Change from Assets/Liabilities | NA | -5.61 | -25.04 | -11.14 | -13.25 |
Net Cash from Discontinued Operations | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Other Operating Activities | NA | 38.52 | 21.71 | 13.09 | 9.68 |
Net Cash From Operating Activities | NA | -33.46 | -47.77 | -34.50 | -31.67 |
Property & Equipment | NA | -0.72 | -0.66 | -0.74 | -0.51 |
Acquisition/ Disposition of Subsidiaries | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Investments | NA | 5.88 | 12.07 | 31.85 | 25.37 |
Other Investing Activities | NA | -11.86 | -11.86 | -11.86 | 0.00 |
Net Cash from Investing Activities | NA | -6.71 | -0.45 | 19.25 | 24.86 |
Uses of Funds
3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 | |
---|---|---|---|---|---|
Issuance (Repurchase) of Capital Stock | NA | 4.90 | 3.93 | 2.78 | 1.64 |
Issuance (Repayment) of Debt | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Increase (Decrease) Short-Term Debt | NA | -10.03 | -3.48 | 0.00 | 0.00 |
Payment of Dividends & Other Distributions | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Other Financing Activities | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Net Cash from Financing Activities | NA | -5.13 | 0.45 | 2.78 | 1.64 |
Effect of Exchange Rate Changes | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Net Change In Cash & Equivalents | NA | -45.30 | -47.78 | -12.47 | -5.17 |
Cash at Beginning of Period | NA | 94.17 | 94.17 | 94.17 | 94.17 |
Cash at End of Period | NA | 48.88 | 46.40 | 81.71 | 89.00 |
Diluted Net EPS | NA | -0.19 | -0.09 | -0.08 | -0.18 |